共 58 条
[1]
Govan JR(1996)Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia Microbiol Rev 60 539-574
[2]
Deretic V(1997)Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection Infect Immun 65 3838-3846
[3]
Boucher JC(2002)Lung infections associated with cystic fibrosis Clin Microbiol Rev 15 194-222
[4]
Yu H(1999)Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype Infect Immun 67 4744-4750
[5]
Mudd MH(2013)Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study J Antimicrob Chemother 68 1763-1771
[6]
Deretic V(2010)Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1 J Antimicrob Chemother 65 1399-1404
[7]
Lyczak JB(2015)Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis Diagn Microbiol Infect Dis 83 53-55
[8]
Cannon CL(2009)Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates Int J Antimicrob Agents 34 402-406
[9]
Pier GB(2010)Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients Clin Microbiol Infect 16 1482-1487
[10]
Parad RB(2016)Successful use of ceftolozane-tazobactam to treat a pulmonary exacerbation of cystic fibrosis caused by multidrug-resistant Pseudomonas aeruginosa Pharmacotherapy. 36 e154-e159